Dupilumab Compassionate Use Study
|Study Type:||Expanded Access What is Expanded Access?|
|Official Title:||Dupilumab Compassionate Use Study|
This study is being undertaken to determine whether dupilumab has efficacy in extremely severe asthma, and to allow a very severe asthma patient, who has been tried on nearly every immunosuppressive drug, early access to a potentially effective therapy.
The patient will continue in the study indefinitely. Safety will be evaluated and serious adverse events will be reported.
Please refer to this study by its ClinicalTrials.gov identifier: NCT03020810
|Contact: Catherine Vitari, RN BSN AE-Cemail@example.com|